LPU
CLVS

Lansdowne Partners (UK)’s Clovis Oncology, Inc. CLVS Stock Holding History

Lansdowne Partners (UK)’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-559,534
Closed -$10.7M – 60
2016
Q1 		$10.7M Hold
559,534
– – 0.08% 19
2015
Q4 		$19.6M Buy
+559,534
New +$36.1M 0.13% 20

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lansdowne Partners (UK)'s CLVS Position: Q2 2016 in Review

Lansdowne Partners (UK) sold out of Clovis Oncology, Inc. (CLVS) in Q2 2016, closing a stake of 559,534 shares — an estimated $10.7M sold.

Lansdowne Partners (UK) first reported a position in CLVS in Q4 2015 and held it in 2 quarters. The position peaked at $19.6M in Q4 2015. 122 funds tracked by Wall St. Rank hold CLVS as of Q2 2016.

  • Lansdowne Partners (UK) reported no remaining Clovis Oncology, Inc. position as of Q2 2016 after selling out during the quarter.
  • Lansdowne Partners (UK) sold 559,534 Clovis Oncology, Inc. shares in Q2 2016, an estimated $10.7M.
  • Lansdowne Partners (UK) first reported a position in Clovis Oncology, Inc. in Q4 2015 and held it in 2 quarters.
  • Lansdowne Partners (UK)'s Clovis Oncology, Inc. position peaked at $19.6M in Q4 2015.
  • 122 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2016.

Based on Lansdowne Partners (UK)'s 13F filing for Q2 2016, filed 15 Aug 2016.